Twin-to-twin transfusion syndrome: Perinatal outcome and recipient heart disease according to treatment strategy

2012 ◽  
Vol 49 (1) ◽  
pp. E28-E34 ◽  
Author(s):  
Catherine Barrea ◽  
Christian Debauche ◽  
Olivia Williams ◽  
Stéphanie Jasienski ◽  
Patricia Steenhaut ◽  
...  
2000 ◽  
Vol 70 ◽  
pp. D70-D70
Author(s):  
K. Vasishta ◽  
H. Sawhney ◽  
N. Aggarwal ◽  
V. Suri ◽  
A. Grover ◽  
...  

2020 ◽  
Vol 34 (6) ◽  
pp. 637-644
Author(s):  
Stine Kloster ◽  
Anne‐Marie Nybo Andersen ◽  
Søren Paaske Johnsen ◽  
Dorte Guldbrand Nielsen ◽  
Annette Kjær Ersbøll ◽  
...  

2006 ◽  
Vol 25 (8) ◽  
pp. 979-982 ◽  
Author(s):  
Katherine Bianco ◽  
Maria Small ◽  
Svena Julien ◽  
Trace Kershaw ◽  
Maaike Michon ◽  
...  

Author(s):  
Vikas Yadav ◽  
J. B. Sharma ◽  
Garima Kachhawa ◽  
Alka Kriplani ◽  
Reeta Mahey ◽  
...  

Background: Rheumatic heart disease remains the commonest heart disease in India with mitral stenosis being the most common lesion and is associated with significant maternal and perinatal mortality and morbidity. The objective of this study was to compare maternal and perinatal outcome in women with rheumatic heart valvular disease who had no surgery or had percutaneous balloon mitral valvuloplasty (PBMV) or had valvular replacement surgery.Methods: It was a retrospective study in 113 women with rheumatic heart disease with various valvular lesion admitted in the hospital in previous 10 years. There were 58 (51.35%) patients without cardiac surgery (Group 1), 24 (21.23%) with PTMC (Group 2) and 31 (27.43%) with valve replacement surgery (Group 3). Maternal and perinatal outcome were compared in three groups.Results: The baseline characteristics were similar in the three group. In cardiac complications New York Heart Association (NYHA) deterioration was significantly higher (24.1%) in non-operated group (Group 1) as compared to Group 2 (12.3%) and Group 3 (16.1%). There was no difference in Group 2 and Group 3. Need of cardiac medication (digoxin) was also highest (67.2%) in Group 1 as compared to Group 2 (24.6%) (p = 0.002) and Group 3 (38.7%) (p = 0.001) but no difference in Group 2 and Group 3. Anticoagulant were given to significantly higher number (54.8% of cases in Group 3 (valve replacement) as compared to Group 1 (3.4%) and Group 2 (12.5%). There was no significant difference in obstetric events and mode of delivery in the three groups. Similarly, there was no difference in fetal outcome in the three groups as regard to mean birth weight, APGAR score, fetal growth restriction, fetal or neonatal death or congenital anomalies in the three groups.Conclusions: Cardiac surgery before or during pregnancy did not significantly improve maternal or perinatal outcome. Only cardiac events and need of medication was reduced with surgery. Hence surgery should be performed judiciously in selected cases.


2021 ◽  
Vol 2 (1) ◽  
pp. 1-7
Author(s):  
Joseph Relmasira ◽  
Budi Wicaksono

Background: Cardiac disease is 1 of the major causes of maternal mortality. Mitral Stenosis (MS) is a particularly high-risk condition for a pregnant woman in emerging countries, the main cause of MS is a complication from rheumatic heart disease. Objective: To study the maternal and perinatal outcome of pregnancies complicated by mitral stenosis from rheumatic heart disease. Methods: We conduct a cross-sectional retrospective study using electronic medical data records in dr. Soetomo General Hospital over the period of 3 years from 2015 – 2017 involving 36 cases of pregnant women complicated by rheumatic mitral stenosis. The maternal and perinatal outcome was reviewed. Result: Most of the pregnant women with rheumatic mitral stenosis were at 29 - 34 weeks of gestational age. Majority of the patient (61,1 %) was in NYHA II classification for heart failure degree. The Degree of MS was moderate (75 %) and severe (25 %), with a maternal mortality rate was 4/36 patients (11,1 %), and all of the patients were with severe MS had class III/IV heart failure. The main reason for hospital admission was heart failure (50 %). 38 % of women with NYHA Class III/IV had severe MS. Most accompanying valve diseases occur at the patient with severe MS, with Tricuspid Regurgitation as the most accompanying valve disease (66,67 %) followed by Mitral Regurgitation (36,11 %) and Aortic Regurgitation (25 %). Percutaneous Transmitral Valve Commissurotomy (PTMC) was the chosen surgical intervention for valve correction. For a patient with Moderate MS, 6/8 (75 %) of the pregnancy terminated at ³ 34 weeks of gestational age, compared with 18/28 (64,28 %) patient with Severe MS the pregnancy terminated at < 34 weeks of gestational age. Cesarean section was the most chosen method of delivery for most of the cases. Fetal weight (4/7 cases) at delivery for Moderate MS was > 2500 g, compared with (7/18 cases) was < 2000 g for Severe MS. APGAR Score for Moderate MS cases was 8-10 for 5/7 cases, compared with Severe MS, 16/24 cases were < 8. Conclusions: Cardiac and obstetric complications from rheumatic mitral disease remain a major challenge in this disease. Early diagnosis and management with good adherent to pre-conceptional and prenatal care remain a key factor for preventing maternal and fetal morbidity and mortality.


2018 ◽  
Vol 6 (3) ◽  
pp. 291-296
Author(s):  
Rita Saxena ◽  
◽  
Vasavi Bysani ◽  
Anjana Verma ◽  
Anuj Pandya ◽  
...  

2015 ◽  
Vol 41 (6) ◽  
pp. 896-903 ◽  
Author(s):  
Lisa Story ◽  
Dharmintra Pasupathy ◽  
Srividhya Sankaran ◽  
Gurleen Sharland ◽  
Pippa Kyle

2020 ◽  
Vol 76 (5) ◽  
pp. 438-445
Author(s):  
Aya Miyazaki ◽  
Jun Negishi ◽  
Yohsuke Hayama ◽  
Etsuko Tsuda ◽  
Osamu Yamada ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document